The company designed the Navitor system for treating people with severe aortic stenosis at high or extreme risk for open-heart surgery. It adds to Abbott’s transcatheter structural heart portfolio of less invasive treatment options for serious heart diseases.
Abbott entered the U.S. TAVR and TAVI market in 2021 with FDA approval of its Portico with FlexNav system. The company is seeking to compete in a space that Edwards Lifesciences and Medtronic have dominated in the U.S.
